NEW YORK – Swedish diagnostic companies Attana and Capitainer announced on Monday that they have inked a collaboration deal to clinically validate their technologies for COVID-19 immune profiling.
The companies will validate Capitainer's dried blood spot sampling cards, called Capitainer qDBS cards, which are intended for self-sampling, with Attana's SARS-CoV-2 immunoassay kit for use with its AVA biosensor system, both of which received CE marking in June. The goal of the collaboration is to offer broader and more patient-centric blood sampling solutions by including the use of capillary blood samples in addition to serum samples, they said in a statement.
Financial and other terms of the deal were not disclosed.
The firms intend to perform a larger patient study within the framework of a study Attana is already conducting on COVID-19 immune profiling, they said. That ongoing study is being conducted with Linnaeus University and Region Kalmar.
Capitainer's collection device allows for blood sampling of exact volumes and sampling across a wider variety of places, since it can be conducted by patients themselves and sent via mail to a lab for analysis, the companies said.
"In addition to an ongoing need for COVID-19 immunity and vaccine efficacy studies, there is much to suggest that the need for remote sampling will continue to grow in the coming years within clinical diagnostics, drug development, as well as in academic research fields such as immunology and virology," Samir Fostock, head of Attana Diagnostics, said in a statement. "The Attana AVA system in combination with Capitainer qDBS will be able to offer our customers and their patients high quality diagnostic analyses in a wider scope of studies than possible today."